today EuroPerio7 Vienna 7 June 2012
Seventh congress of the European Federation of Periodontology to present the latest research and cutting-edge technology
/ Colgate-Palmolive launches Oral Health Network
/ Welcome
/ “Our growth is definitely driven by innovation and quality” - An interview with Gilles Pierson - CEO of the Acteon Group
/ “Good long-term treatment results depend on periodontal maintenance therapy” - An interview with Dr Oystein Fardal - Norway
/ Science & Practice
/ Exhibitors List
/ Industry
/ What’s on
Array
(
[post_data] => WP_Post Object
(
[ID] => 57652
[post_author] => 0
[post_date] => 2012-06-06 15:57:18
[post_date_gmt] => 2012-06-06 15:57:18
[post_content] =>
[post_title] => today EuroPerio7 Vienna 7 June 2012
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => today-europerio-7-vienna-7-june-2012-3512
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-21 23:05:15
[post_modified_gmt] => 2024-10-21 23:05:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://e.dental-tribune.com/epaper/today-europerio-7-vienna-7-june/
[menu_order] => 0
[post_type] => epaper
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[id] => 57652
[id_hash] => 138eed9443cff852fde5b514f1cf42c633d882604a2a37bc1270bfaf74166ab7
[post_type] => epaper
[post_date] => 2012-06-06 15:57:18
[fields] => Array
(
[pdf] => Array
(
[ID] => 57653
[id] => 57653
[title] => today Europerio 7 Vienna, 7 June.pdf
[filename] => today Europerio 7 Vienna, 7 June.pdf
[filesize] => 0
[url] => https://e.dental-tribune.com/wp-content/uploads/today Europerio 7 Vienna, 7 June.pdf
[link] => https://e.dental-tribune.com/epaper/today-europerio-7-vienna-7-june-2012-3512/today-europerio-7-vienna-7-june-pdf-2/
[alt] =>
[author] => 0
[description] =>
[caption] =>
[name] => today-europerio-7-vienna-7-june-pdf-2
[status] => inherit
[uploaded_to] => 57652
[date] => 2024-10-21 23:05:09
[modified] => 2024-10-21 23:05:09
[menu_order] => 0
[mime_type] => application/pdf
[type] => application
[subtype] => pdf
[icon] => https://e.dental-tribune.com/wp-includes/images/media/document.png
)
[cf_issue_name] => Europerio 7 Vienna, 7 June 2012
[cf_edition_number] => 3512
[contents] => Array
(
[0] => Array
(
[from] => 01
[to] => 01
[title] => Seventh congress of the European Federation of Periodontology to present the latest research and cutting-edge technology
[description] => Seventh congress of the European Federation of Periodontology to present the latest research and cutting-edge technology
)
[1] => Array
(
[from] => 01
[to] => 01
[title] => Colgate-Palmolive launches Oral Health Network
[description] => Colgate-Palmolive launches Oral Health Network
)
[2] => Array
(
[from] => 02
[to] => 02
[title] => Welcome
[description] => Welcome
)
[3] => Array
(
[from] => 04
[to] => 04
[title] => “Our growth is definitely driven by innovation and quality” - An interview with Gilles Pierson - CEO of the Acteon Group
[description] => “Our growth is definitely driven by innovation and quality” - An interview with Gilles Pierson - CEO of the Acteon Group
)
[4] => Array
(
[from] => 06
[to] => 06
[title] => “Good long-term treatment results depend on periodontal maintenance therapy” - An interview with Dr Oystein Fardal - Norway
[description] => “Good long-term treatment results depend on periodontal maintenance therapy” - An interview with Dr Oystein Fardal - Norway
)
[5] => Array
(
[from] => 07
[to] => 07
[title] => Science & Practice
[description] => Science & Practice
)
[6] => Array
(
[from] => 08
[to] => 08
[title] => Exhibitors List
[description] => Exhibitors List
)
[7] => Array
(
[from] => 10
[to] => 13
[title] => Industry
[description] => Industry
)
[8] => Array
(
[from] => 14
[to] => 14
[title] => What’s on
[description] => What’s on
)
)
[seo_title] =>
[seo_description] =>
[seo_keywords] =>
[fb_title] =>
[fb_description] =>
)
[permalink] => https://e.dental-tribune.com/epaper/today-europerio-7-vienna-7-june-2012-3512/
[post_title] => today EuroPerio7 Vienna 7 June 2012
[client] =>
[client_slug] =>
[pages_generated] =>
[pages] => Array
(
[1] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-0.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-0.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-0.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-0.jpg
[1000] => 57652-8d03f090/1000/page-0.jpg
[200] => 57652-8d03f090/200/page-0.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[2] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-1.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-1.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-1.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-1.jpg
[1000] => 57652-8d03f090/1000/page-1.jpg
[200] => 57652-8d03f090/200/page-1.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[3] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-2.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-2.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-2.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-2.jpg
[1000] => 57652-8d03f090/1000/page-2.jpg
[200] => 57652-8d03f090/200/page-2.jpg
)
[ads] => Array
(
[0] => Array
(
[post_data] => WP_Post Object
(
[ID] => 57654
[post_author] => 0
[post_date] => 2024-10-21 23:05:09
[post_date_gmt] => 2024-10-21 23:05:09
[post_content] =>
[post_title] => epaper-57652-page-3-ad-57654
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => epaper-57652-page-3-ad-57654
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-21 23:05:09
[post_modified_gmt] => 2024-10-21 23:05:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://e.dental-tribune.com/ad/epaper-57652-page-3-ad/
[menu_order] => 0
[post_type] => ad
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[id] => 57654
[id_hash] => 769a7fe627aa8da41c3ebca66ff20cf3e7f15316211a8ad1d616c1a32e84a623
[post_type] => ad
[post_date] => 2024-10-21 23:05:09
[fields] => Array
(
[url] => http://www.dental-tribune.com/companies_66_straumann_ag.html
[link] => URL
)
[permalink] => https://e.dental-tribune.com/ad/epaper-57652-page-3-ad-57654/
[post_title] => epaper-57652-page-3-ad-57654
[post_status] => publish
[position] => 3.77,1.91,91.68,96.72
[belongs_to_epaper] => 57652
[page] => 3
[cached] => false
)
)
[html_content] =>
)
[4] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-3.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-3.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-3.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-3.jpg
[1000] => 57652-8d03f090/1000/page-3.jpg
[200] => 57652-8d03f090/200/page-3.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[5] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-4.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-4.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-4.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-4.jpg
[1000] => 57652-8d03f090/1000/page-4.jpg
[200] => 57652-8d03f090/200/page-4.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[6] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-5.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-5.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-5.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-5.jpg
[1000] => 57652-8d03f090/1000/page-5.jpg
[200] => 57652-8d03f090/200/page-5.jpg
)
[ads] => Array
(
[0] => Array
(
[post_data] => WP_Post Object
(
[ID] => 57655
[post_author] => 0
[post_date] => 2024-10-21 23:05:09
[post_date_gmt] => 2024-10-21 23:05:09
[post_content] =>
[post_title] => epaper-57652-page-6-ad-57655
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => epaper-57652-page-6-ad-57655
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-21 23:05:09
[post_modified_gmt] => 2024-10-21 23:05:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://e.dental-tribune.com/ad/epaper-57652-page-6-ad/
[menu_order] => 0
[post_type] => ad
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[id] => 57655
[id_hash] => 1dbbdbeb47dac227b8da70fdb52982a270ecb8d261ff624996a9bf074d8bee48
[post_type] => ad
[post_date] => 2024-10-21 23:05:09
[fields] => Array
(
[url] => http://www.dental-tribune.com/companies_994_greater_new_york_dental_meeting.html
[link] => URL
)
[permalink] => https://e.dental-tribune.com/ad/epaper-57652-page-6-ad-57655/
[post_title] => epaper-57652-page-6-ad-57655
[post_status] => publish
[position] => 5.33,43.44,53.07,52.19
[belongs_to_epaper] => 57652
[page] => 6
[cached] => false
)
)
[html_content] =>
)
[7] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-6.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-6.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-6.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-6.jpg
[1000] => 57652-8d03f090/1000/page-6.jpg
[200] => 57652-8d03f090/200/page-6.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[8] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-7.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-7.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-7.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-7.jpg
[1000] => 57652-8d03f090/1000/page-7.jpg
[200] => 57652-8d03f090/200/page-7.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[9] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-8.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-8.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-8.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-8.jpg
[1000] => 57652-8d03f090/1000/page-8.jpg
[200] => 57652-8d03f090/200/page-8.jpg
)
[ads] => Array
(
[0] => Array
(
[post_data] => WP_Post Object
(
[ID] => 57656
[post_author] => 0
[post_date] => 2024-10-21 23:05:09
[post_date_gmt] => 2024-10-21 23:05:09
[post_content] =>
[post_title] => epaper-57652-page-9-ad-57656
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => epaper-57652-page-9-ad-57656
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-21 23:05:09
[post_modified_gmt] => 2024-10-21 23:05:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://e.dental-tribune.com/ad/epaper-57652-page-9-ad/
[menu_order] => 0
[post_type] => ad
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[id] => 57656
[id_hash] => 35dbfccf3a73a835b015070b6659b851044968ea5969e0fa021c59fc1191d106
[post_type] => ad
[post_date] => 2024-10-21 23:05:09
[fields] => Array
(
[url] => http://www.dental-tribune.com/companies/content/id/3377/code/acteon_group
[link] => URL
)
[permalink] => https://e.dental-tribune.com/ad/epaper-57652-page-9-ad-57656/
[post_title] => epaper-57652-page-9-ad-57656
[post_status] => publish
[position] => 2.59,2.19,94.81,96.99
[belongs_to_epaper] => 57652
[page] => 9
[cached] => false
)
)
[html_content] =>
)
[10] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-9.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-9.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-9.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-9.jpg
[1000] => 57652-8d03f090/1000/page-9.jpg
[200] => 57652-8d03f090/200/page-9.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[11] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-10.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-10.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-10.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-10.jpg
[1000] => 57652-8d03f090/1000/page-10.jpg
[200] => 57652-8d03f090/200/page-10.jpg
)
[ads] => Array
(
[0] => Array
(
[post_data] => WP_Post Object
(
[ID] => 57657
[post_author] => 0
[post_date] => 2024-10-21 23:05:09
[post_date_gmt] => 2024-10-21 23:05:09
[post_content] =>
[post_title] => epaper-57652-page-11-ad-57657
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => epaper-57652-page-11-ad-57657
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-21 23:05:09
[post_modified_gmt] => 2024-10-21 23:05:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://e.dental-tribune.com/ad/epaper-57652-page-11-ad/
[menu_order] => 0
[post_type] => ad
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[id] => 57657
[id_hash] => b0969bddf72f75da61de8bb35c2760c382529ae75d819fea61a3f4ce5b76e861
[post_type] => ad
[post_date] => 2024-10-21 23:05:09
[fields] => Array
(
[url] => http://www.dental-tribune.com/companies/content/id/25
[link] => URL
)
[permalink] => https://e.dental-tribune.com/ad/epaper-57652-page-11-ad-57657/
[post_title] => epaper-57652-page-11-ad-57657
[post_status] => publish
[position] => 1.81,1.91,93.25,96.18
[belongs_to_epaper] => 57652
[page] => 11
[cached] => false
)
)
[html_content] =>
)
[12] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-11.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-11.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-11.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-11.jpg
[1000] => 57652-8d03f090/1000/page-11.jpg
[200] => 57652-8d03f090/200/page-11.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[13] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-12.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-12.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-12.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-12.jpg
[1000] => 57652-8d03f090/1000/page-12.jpg
[200] => 57652-8d03f090/200/page-12.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[14] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-13.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-13.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-13.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-13.jpg
[1000] => 57652-8d03f090/1000/page-13.jpg
[200] => 57652-8d03f090/200/page-13.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[15] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-14.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-14.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-14.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-14.jpg
[1000] => 57652-8d03f090/1000/page-14.jpg
[200] => 57652-8d03f090/200/page-14.jpg
)
[ads] => Array
(
)
[html_content] =>
)
[16] => Array
(
[image_url] => Array
(
[2000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/2000/page-15.jpg
[1000] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/1000/page-15.jpg
[200] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/200/page-15.jpg
)
[key] => Array
(
[2000] => 57652-8d03f090/2000/page-15.jpg
[1000] => 57652-8d03f090/1000/page-15.jpg
[200] => 57652-8d03f090/200/page-15.jpg
)
[ads] => Array
(
[0] => Array
(
[post_data] => WP_Post Object
(
[ID] => 57658
[post_author] => 0
[post_date] => 2024-10-21 23:05:09
[post_date_gmt] => 2024-10-21 23:05:09
[post_content] =>
[post_title] => epaper-57652-page-16-ad-57658
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => epaper-57652-page-16-ad-57658
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-21 23:05:09
[post_modified_gmt] => 2024-10-21 23:05:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://e.dental-tribune.com/ad/epaper-57652-page-16-ad/
[menu_order] => 0
[post_type] => ad
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[id] => 57658
[id_hash] => e24b820ade223edbd71a0260d2167db622f56151ef40562674b79f646a7a6f84
[post_type] => ad
[post_date] => 2024-10-21 23:05:09
[fields] => Array
(
[url] => http://www.dental-tribune.com/companies/content/id/1558/code/nobel_biocare_holding_ag
[link] => URL
)
[permalink] => https://e.dental-tribune.com/ad/epaper-57652-page-16-ad-57658/
[post_title] => epaper-57652-page-16-ad-57658
[post_status] => publish
[position] => 3.77,2.19,91.68,95.9
[belongs_to_epaper] => 57652
[page] => 16
[cached] => false
)
)
[html_content] =>
)
)
[pdf_filetime] => 1729551909
[s3_key] => 57652-8d03f090
[pdf] => today Europerio 7 Vienna, 7 June.pdf
[pdf_location_url] => https://e.dental-tribune.com/tmp/dental-tribune-com/57652/today Europerio 7 Vienna, 7 June.pdf
[pdf_location_local] => /var/www/vhosts/e.dental-tribune.com/httpdocs/tmp/dental-tribune-com/57652/today Europerio 7 Vienna, 7 June.pdf
[should_regen_pages] => 1
[pdf_url] => https://epaper-dental-tribune.s3.eu-central-1.amazonaws.com/57652-8d03f090/epaper.pdf
[pages_text] => Array
(
[1] =>
Standard_300dpi
EUROPERIO · Vienna · 6–9 June, 2012
Independent news for visitors and exhibitors
6
7
8
Gilles Pierson speaks
Science & Practice
Dental products in focus
Acteon’s Chief Executive Officer on his company’s history, future strategies and what the
company has to offer during Europerio 7.
Europerio speakers provide insights into quality
control of periodontal therapy, vaccination
against periodontitis and the complexity of microbiological infections.
Europerio 7 will be an excellent opportunity to
see state of the art technologies and achievements in the field of periodontology and dental
implants.
»Page 4
»Pages 6–7
»Pages 10 & 12
AD
Û IMPLANT CLEANING
MECTRON MULTIPIEZO PRO
Seventh congress of the European
Federation of Periodontology to present the
latest research and cutting-edge technology
Perio implant event of the year starts in Vienna. (DTI/Photo johny007pan )
Dental professionals from all
over Europe and abroad are expected to gather this morning at
the Reed Exhibitions Congress
Center in Vienna for the Europerio 7 congress. The scientific
event, organised by the Austrian
Society of Periodontology on behalf of the European Federation
of Periodontology, will present
the latest research and technology in the field of periodontology
and dental implantology over the
course of the next three days.
Colgate-Palmolive launches
Oral Health Network
Dental consumables manufacturer Colgate-Palmolive has announced the launch of the Colgate
Oral Health Network for Professional Education and Development — a new
online resource
dedicated to
helping dental
professionals
improve the oral health and wellbeing of their patients. Through a
partnership with the Dental Tribune Study Club, the Network provides access to some of the latest
information and developments in
oral health.
Since December last year, den-
tal professionals are able to access
the free benefits of the Colgate
Oral Health Network including
educational resources such as
live online webinars and ondemand seminars. It is also intended to serve
as an interaction platform
for dental professionals worldwide by incorporating various
cultures and new perspectives
into the educational mix, the company said.
More information is available at
www.colgateoralhealthnetwork.
com.
According to the organiser,
Europerio 7 is aimed at both general practitioners and specialists. Over 100 speakers from Europe and overseas will be presenting the latest insights into
the management and treatment
of periodontal disease, as well as
aspects of dental implant therapy, in over 60 lectures and workshops. A large number of sessions will be also dedicated to
pre-existing medical conditions.
In two of the main sessions (periodontal medicine, and risk factors and their management), reference will be made to important
associations with diabetes, obesity and cardiovascular disease,
the organiser said.
Scientific sessions will start
this morning, with presentations
on periodontal plastic surgery
and new insights into the host re-
sponse in periodontitis. Parallel
lectures on computer-guided
treatment in dental implantology and dental hygiene will also
be held.
In addition, research posters
will be presented throughout the
day. According to the organiser,
over 1,300 abstracts have been
submitted for Europerio 7, a 60
per cent increase compared with
the last congress.
The event has received support by a number of major industry players, including Straumann, Philips, Acteon, MIS and
Nobel Biocare, which have announced a number of seminars
and corporate workshops to be
held during Europerio 7. New
products and technologies will
be on display during the trade exhibition, which is joined by over
100 companies from around the
globe.
“With particular emphasis on
research that will address the
global scientific community and
give them a forum, my expectations for this conference and its
acceptance are especially high,”
congress chairman and board
member of the Austrian Society
of Periodontology, Dr Gernot
Wimmer, told Dental Tribune
Austria. “From a professional
viewpoint, I am excited to see the
results of the attendance at our
different events, as these evaluations will be vital for the planning of future congresses.”
This year is the seventh time
that the congress is being organised by the European Federation
of Periodontology in collaboration with one of its member periodontal societies. The federation,
which is based in Madrid, was
founded in 1991 in order to facilitate research in periodontology
and dental implantology. Its
main congress is held every
three years in different host
cities in Europe. The last congress in Stockholm in 2009 saw
the attendance of over 6,600 visitors from 82 countries.
For more news from this year’s
Europerio in Vienna, please scan
the QR code at the bottom right or
visit www.dental-tribune.com/europerio7.
[2] =>
Standard_300dpi
welcome
2
EUROPERIO Vienna 2012–7 June
“Oral health is a substantial part of general health and well-being”
A welcome message by Alois Stöger, Minister of Health in Austria
Herewith, I would like to welcome you to the seventh conference of the European Federation of Periodontology. It is indeed a great honour and pleasure for me that this leading
periodontology and dental im-
plantology congress is being
held in Vienna. I would like to
extend my thanks to the head of
the organising committee, Dr
Gernot Wimmer, and his team,
who have prepared a great and
diverse scientific programme.
Once again, Europerio will address important issues in dentistry. The focus of interest will
be the latest trends and research
findings in the fields of periodontology, implantology and dental
hygiene. As far as we know today,
oral health is a substantial part of
general health and maintaining
one’s own teeth contributes significantly to one’s quality of life
and well-being. One of the main
causes of tooth loss in adults is periodontitis. Since non-treated pe-
AD
Alois Stöger (DTI/Photo Courtesy of the
Federal Ministry of Health, Austria)
riodontal disease increases the
risk of systematic non-communicative diseases, such as diabetes or heart and circulatory
disease, it is essential to direct efforts towards preventing and
treating those conditions, as well
as towards combating shared
risk factors, including poor nutritional habits and smoking.
Results from oral health surveys conducted in Austria reflect
good oral health in our adult population. Fortunately, tooth loss
and edentulism have become
rare. At the same time, the percentage of prosthetic restorations has increased, with an obvious trend from removable dentures towards high-quality tooth
replacements. Owing to the use
of modern technologies and advancements in dental materials,
implantology has now become inseparable from modern dentistry.
One of the main challenges for
health systems in the 21st century is equality of opportunity.
We are aware of the fact that socially and educationally disadvantaged groups have a lower
likelihood of good health. Studies conducted at national and international level have demonstrated that this is also true of
oral health. Social inequalities
equal inequalities in oral health.
As Minister of Health in Austria,
one of my primary goals is to promote fairness of opportunity in
both general and oral health.
On that note, let me wish you
an interesting and successful
conference, as well as plenty of
opportunities for exchanging information with your peers. In addition to the professional programme offered at Europerio, I
hope that your stay will give you
the chance to explore our city’s
many cultural and culinary highlights.
I wish you a pleasant stay in
Vienna.
08 | 09 | 10 | NOV | 2012 | EUROPARQUE | PORTO | PORTUGAL
Yours faithfully,
Alois Stöger
[3] =>
Standard_300dpi
STRAUMANN EMDOGAIN 015
DESIGNED TO REBUILD
®
Cost effective treatment option
Combine with various* bone grafting material
Excellent clinical results1,2,3
Clinical long-term benefit4,5
Improved patient satisfaction6,7
0.7 ml
0.3 ml
0.15 ml
W
E
N
51
0
IN
A
M
G
O
5
E M D IVNE®RY D0A1Y
E
A
R
G
O
O
F
D
®
*BoneCeramic™, autograft, allograft, bone-derived xenograft, ß-Tricalcium phosphate or
bioactive glass
Tonetti et al. J. Clin. Periodontol. 2002;29:317 – 325 2 Froum et al. J. Periodontol. 2001;72:25–34
McGuire et al. J. Periodontol. 2003;74:1110 & 1126 4 Heden et al. J. Periodontol. 2006;77:295 – 301
5
Sculean et al. Int. JPRD. 2007;27:221 – 229 6 Jepsen et al. J. Periodontol. 2004;75:1150 – 1160
7
Sanz et al. J. Periodontol. 2004;726 – 733
1
3
[4] =>
Standard_300dpi
4
news
EUROPERIO Vienna 2012–7 June
“Our growth is definitely driven by innovation and quality”
An interview with Gilles Pierson, CEO of the Acteon Group
During the 2011 conference
of the Association Dentaire
Française (ADF) in Paris, Gilles
Pierson, CEO of the Acteon
Group, gave insight into his company’s history, new products and
future strategies.
Your business units Satelec,
Pierre Rolland and Sopro
were unified under the
Acteon Group in 2003, followed by your Italian business unit, De Götzen, which
joined the group in 2006. At
IDS Cologne 2011, you introduced your new corporate
identity and the new Acteon
logo. What was the main reason for this rebranding?
The change in the group’s
name is due to the fact that at the
very beginning in 1980, Satelec
existed on its own. Pierre Rolland
merged with Satelec in 1985 to
become Satelec–Pierre Rolland.
After 1995, we decided to grow
the company through acquisitions, so we acquired different
companies like Sopro and De
Götzen.
It would not have
been feasible to
have named the
group Satelec,
Pierre Roland,
Sopro, De Götzen
and so on. We saw
the necessity for a
group name while
maintaining the companies’ individual names. So the group is
now named Acteon but the different companies that we acquired
and that merged are identified as
companies with their own history and their own products. This
is also good for the employees,
who still identify with their original companies while belonging
to a large group.
So we have kept the history of
each company, but we have
grouped them under the umbrella of Acteon. Satelec is still
known in countries like France.
Pierre Rolland, which is a 60year-old company, is still famous,
so it’s a little bit difficult to introduce the name of Acteon. Eight
years on, awareness is growing,
although the individual company names of Pierre Rolland
and Satelec are still better known
than the umbrella group of
Acteon.
In countries where our history is shorter, like the USA, Asia
or Australia, Acteon is now
known as a company, and the different companies like Satelec,
Pierre Rolland and Sopro as divisions. We found a way to keep
the identity of each company in
the group, while building a brand
name that encompasses all of
them.
With a turnover of €113 million and a growth rate of 16 %
in 2010, last year was a tremendous success for the Acteon
Group. Over two third of sales
were recorded in France. How
was 2011 for you, and which
markets do you consider most
important for the group?
The year 2010 was another big
and successful year with a 16 %
increase. In 2011, we expect another 9 % increase in sales, which
is good if you consider the economic situation. Europe will account for a stable 2 % and the US
for 10 %. But the highest growth
we are experiencing is in China,
at approximately 20 %. In general, Asia currently accounts for
20 % of our global sales, so if we
achieve a 20 % increase, we will
be very satisfied. Countries like
Japan and India in particular are
very strong markets for us, as
was Thailand until November,
before floods plagued the country.
2011 and the coming years
will definitely be driven by Asia,
and especially by China, where
we have been doing business
since 1987. We now have a team
of 40 people there and expect an
average growth of 30 % over the
next five years. China is definitely a booming market.
When we talk to other European companies that sell on
the Chinese market, they often mention price sensitivity
and the need to adapt to the local price level.
No, I don’t think it’s a question
of price—it’s a question of mentality in China. They have cheap
copies of all our products there.
Twenty years ago, we sued the
copycats. However, we realised
that this was not productive because if the company simply
closes and reopens in the next
garage, you are fighting a lost
cause. More importantly, we realised that the Chinese copies are
our best advertising because the
quality is very poor and the design is just ridiculous. Dentists
first buy a Chinese copy but then
they experience so many problems. As soon as they have the
money to buy a European product at a European price, they will
buy it. The fake Rolex made in
China is sold in Europe, but the
real Rolex made in Switzerland is
sold in China. And the proper
business-orientated Chinese
client with a long-term plan will
never buy a fake product.
On the other hand, we are see-
ing an alarming trend reversal in
Europe. There are so many fake
or copy products from China imported into Europe with a fake CE
number or with a fake ISO 9000.
The customs duties in the Shenzhen area do not block these fake
products, so any kind of product
can enter into Europe. These are
healthcare devices to treat patients and they should not put patients in danger.
Do you believe that you will
still be able to manufacture in
France or in Europe in the future?
Acteon’s policy is to manufacture and conduct research in
Western Europe, and not to manufacture in China, South-East
Asia, Brazil, India, or anywhere
else. Our policy is to produce continuously in Western Europe.
Our factories are in France, Italy
and Germany. Acteon has established itself in a niche of the
health-care market. This market
is driven by quality and innovation. Western Europe is best
known for these qualities and,
consequently, you have to have
your factory here to produce at
such a level and to generate innovation based on the technology.
This is Acteon’s philosophy.
Over the past 30 years, we
have invested a large amount of
the company’s profits in R&D.
We currently have a total of 70
people in our R&D departments
in the different companies, and
our growth is definitely driven
by innovation and quality.
You have invested in the digital dentistry market in particular…
We invest a lot in the digital
dentistry market indeed. This is
one of the fastest-growing markets today and we have reached a
point where we are able to offer
more or less the complete range
of products. Only the panoramic
is missing; however, within the
next five to six years, the panoramic might disappear from
the market and be replaced by
the flat panel instead of the linear panel. We therefore prefer
to concentrate on the flat panel,
with a 2-D or 3-D reconstruction.
No one can deny any longer
that the future of dentistry is digital. For example, at Sopro, we
manufacture a camera to detect
tooth decay with fluorescence
technology. So imaging is one
thing, but with imaging you can
go to diagnosis. Imaging for a
diagnosis is really the key point
of imaging, and if you have a good
diagnosis, you can have a good
treatment.
Your new CBCT System,
WhiteFox, received the red
dot design award in 2011,
which recognises exceptional
Gilles Pierson, CEO of the Acteon Group.
industrial design. What is the
response from the market,
and how are the sales figures
for the WhiteFox system?
We place a heavy emphasis on
design at Acteon for three
reasons. The first reason is that
the dental clinics are usually
well designed because the patient is awake. It is not like a hospital, where the patient is under
anaesthesia and asleep and does
not care about his environment.
In a dental clinic, patients like to
have a nice environment to lower
the stress of the experience.
Another point is that the dental assistant is participating increasingly in the choice of products. The clinical team likes nice
designs and colours, whereas
the dentist tends to be more attracted by technical features. But
the dental assistant is playing an
increasingly important role in
decision-making when it comes
to new acquisitions.
The WhiteFox was very well
received by the market. The design is nice, but the technology
is really advanced. For example,
WhiteFox is the only scanner of
its kind to feature a Hounsfield
units calibration. This calibration is used for measuring bone
density in order to allow for
perfect planning and, if needed,
for bone grafting prior to implantations.
Since the introduction of conebeam technology to general dental and maxillo-facial surgery,
ENT surgeons have become increasingly attracted to this form
of technology and are thus becoming a very important market
segment for this kind of product.
The large viewing area for the
ear, nose and throat is especially
convenient. We have good syner-
gies with our medical division,
which is also specialised in the
ENT area. You see, there are
many bridges between the dental
and medical fields, between endoscopy in the medical and imaging in the dental field, between
radiology in the dental and imaging in hospitals or ENT.
We are pleased with the cone
beam, and the sales figures are
within our expectations.
You are Platinum sponsor of
the upcoming Europerio Congress in Vienna. What can visitors expect from Acteon
there?
Basically, we are very involved in preventive and conservative dentistry. Periodontics
has always played a major role in
these areas and Europerio is considered to be the leading congress in this specialty worldwide. We have purposefully chosen to become Platinum sponsor
of the congress because of the
quality of its scientific programme and the excellent standing of the congress in the dental
community.
Acteon will stage sponsored
sessions on Wednesday, 6 June,
from 16:00 to 17:00 (this includes a session hosted by Dr
Bennani entitled “A new gingival retraction technique for implants”). On Friday, 8 June, from
12:15 to 13:45, there will be a
novel procedure for evaluating
plaque status and soft-tissue inflammation using an intraoral
camera. These sessions will be
of interest to dental hygienists,
general dentists as well as periodontists. The crème de la crème
of international speakers will
reveal tips and tricks from their
professional lives, and we invite
everyone cordially to join us in
Vienna. DT
[5] =>
Standard_300dpi
Philips
Sonicare
AirFloss
An easier way
to clean in-between
Cleaning in-between is too troublesome for your patients?
The Philips Sonicare AirFloss is specifically designed to give your patients an easy, quick
and effective way to clean interproximally. It features the patented microburst technology
that shoots microdroplets of air and water to remove plaque biofilm between teeth,
and it is proven to be safe and gentle on gums and teeth.
s %ASY simple one-button use; as easy as a mouse-click
s &AST cleans between all teeth in just 60 seconds
s %FFECTIVE removes interproximal plaque biofilm
s DAY MONEY BACK GUARANTEE offers patients who do
not clean in-between teeth regularly the opportunity
to try out the AirFloss without any risk.
Visit the Philips booth at Europerio 7 (hall A, G 34) for more information
about the Sonicare AirFloss.
[6] =>
Standard_300dpi
science & practice
6
EUROPERIO Vienna 2012–7 June
“Good long-term treatment results depend on
periodontal maintenance therapy”
An interview with Dr Oystein Fardal, Norway
According to Norwegian dentist Dr Oystein Fardal, quality
control in periodontal therapy is
significantly lacking. Today international had the opportunity to
speak with him at Europerio 7
about the challenges of establishing a universal model and the
benefit of quality control to periodontal treatment outcomes.
Today international: Dr Fardal,
your presentation at this Europerio congress is titled
“Quality control in periodontal therapy”. Could you explain this concept in more detail?
Dr Oystein Fardal: The aim of
my presentation here at Euro-
perio 7 is to describe how quality
control can be measured and applied to periodontal therapy. The
main objectives are to determine
the stages of periodontal therapy
during which control measures
should be considered and which
parameters are suitable for
measurement. I will also aim at
identifying benefits for patient
and clinician, as well as the longterm implications of quality-control measures in periodontal
therapy.
From your perspective, is
quality control in periodontal
therapy generally lacking?
Unfortunately, little work has
been done with regard to this im-
portant aspect of periodontal
therapy. What has been achieved
so far has been somewhat sporadic, without an overall plan of
what a quality-control model
should be based upon.
ready a challenge for periodontists today and most likely to increase with time. For example, we
still do not have a proven universal protocol for the treatment of
peri-implantitis.
What are the main challenges
in periodontal treatment
nowadays and which aspects
of therapy or the methods are
most affected?
The emphasis in periodontal
therapy seems to have shifted
somewhat from saving teeth with
doubtful and poor prognoses to
replacing them with implants.
However, with more implants being placed, more complications
need to be dealt with. This is al-
When it comes to traditional
periodontal therapy, the main
challenges are associated with
the management of maintenance
treatment.
AD
MARK YOUR CALENDAR
Scienc Meeng:
Friday - Wednesday,
November 23 - 28
Exhibit Dates:
Sunday - Wednesday,
November 25 - 28
A A N C
Never a pre-registraon fee at the
Greater New York Dental Meeng
M H 600 EXHB
Jacob K. Javits Convenon Center 11th Ave.
between 34-39th Streets (Manhaan)
Q
New York Marrio Marquis otel
LV D A - N T
L D TH
S AV
M TH 350 S P
Seminars, ands-on Workshops, Essays
& Scienc Poster Sessions as well as
Specialty and Auxiliary Programs
E P
V
S P H E F
E N Y C B
H V
H !
Sponsored by the New York County Dental Society and the Second District Dental Society
FOR MORE INFORMATION:
Greater New York Dental Meeng®
570 Seventh Avenue - Suite 800
New York, NY 10018 USA
Tel: (212) 398-6922 / Fax: (212) 398-6934
E-mail: victoria@gnydm.com
You have been campaigning
for the use of periodontal
maintenance therapy programmes for years. How could
such a programme contribute
to the quality of treatment?
Periodontal maintenance programmes have been in existence
for a long time and so has the
knowledge of the importance of
such programmes. My research
merely reiterates the fact that
good long-term treatment results
depend on periodontal maintenance therapy.
In your studies, you have
found that compliance with
these programmes is generally low among patients. Why
is that and what are your recommendations for improving
compliance?
With few exceptions, the literature reports low rates of compliance with maintenance therapy
but this is not a problem specifi-
be important when considering
improvements in patient compliance.
There are quality-control systems in development around
the world. Are you aware of
those systems, and what are
their benefits and shortcomings?
I am aware of some excellent
research being carried out that
can be applied to quality-control
systems. The fact that this work is
being carried out in different areas of the world is beneficial for
agreeing on a universal model for
quality control of periodontal
therapy. However, I do not know
enough of the details of the work
to comment on any shortcomings.
How do new treatment methods or tools contribute to
quality control of periodontal
therapy?
It is not so much that new
methods or tools contribute to
quality control as the fact that
“Any model for quality
control will have to be
designed in such a manner
that it can be applied to both
new and established
treatment methods or tools.”
cally relating to periodontal therapy. All treatment protocols,
medical or dental, for which the
patient is required to participate
are confronted with similar problems.
A number of psychological
theories have been suggested to
explain non-compliance. It is also
known that age, sex, geographic
and cultural differences play a
significant role. One of my papers points out that the referring
dental practitioner could be a decisive factor. Thus, differences in
dental practice profile and treatment philosophies are likely to
these new methods need to have
quality control applied to them.
Any model for quality control
will have to be designed in such a
manner that it can be applied to
both new and established treatment methods or tools. The basic
design of such a model requires
the user to document outcome,
deviations, financial implications and cost effectiveness of
the particular treatment. For example, such a model could be applied to new regenerative procedures or materials.
Thank you very much for this
interview.
[7] =>
Standard_300dpi
EUROPERIO Vienna 2012–7 June
science & practice
7
Vaccination against periodontitis—myth or reality?
By Professor Lior Shapira, Hadassah Medical Center, Hebrew University, Israel
Prevention of disease, in this
case chronic periodontitis, is always better than cure. In many
cases, vaccination has turned out to
be an easy and inexpensive way to
prevent the emergence of disease
in individuals and the community.
Developing a vaccine for periodontitis has been a hot subject for periodontal researchers. After 30 years
of searching for a periodontal vaccine, where do we stand today?
Let me explain briefly how vaccination works. We expose the
body to a weak or dead pathogen, or
even to peptides derived from the
pathogen, which activates B and T
cells that are exposed to the
pathogen. While B cells produce antibodies that can help to kill the
pathogen, T helper cells produce
specific clones, also called cytokines, that activate an immunity
cascade aimed at killing the
pathogen. It is basically a network
of cells and molecules that protects
the body from invaders.
The old dogma was that the role
of vaccination is to induce a humoral immune response, meaning
protection by the production of
memory B cells and antibodies
against the pathogen. This dogma
however is too simple. Recent evidence suggests that immunization
can modulate the host response
and shift the response, a key element in successful protection. The
nature of the cellular response and
which molecules are secreted to the
site by these cells are critical to disease processes, as well as protection.
What is the process of developing a vaccine? First, we have to identify the key pathogens, and then
identify and isolate virulence factors from the pathogens as candidate antigens. The candidate vaccine should be tested first in preclinical models followed by safety
and efficacy tests in humans. Two
years ago, scientists at the University of Melbourne and a biopharmaceutical company announced that
they had developed a vaccine to
treat periodontitis (British Dental
Journal, 2010, Vol. 208, Issue 5).
They claimed to have identified
candidate vaccine antigens for periodontitis and that the new vaccine
targets Porphyromonas gingivalis.
Is this news or just old news? Are
we almost within striking distance
of a vaccine?
In the last 40 years, the key
pathogens for periodontitis were
identified and the short list includes no more than five to seven
pathogens, in which P. gingivalis
plays an important part. Research
by Hajishengallis et al. on animal
models suggested that this lowabundance pathogen is needed
only to initiate the process and
open the door for other bacteria to
induce disease (Cell Host and Microbe, 2011, Vol. 10, Issue 5). This is
a very interesting and attractive hypothesis. In this case, preventing P.
gingivalis from inducing this environmental change will influence
the clinical outcome positively.
Eighteen years ago, a research
group headed by Roy Page from
Seattle was the leader in periodon-
tal vaccination research (Infection
and Immunity, 1994, Vol. 62, Issue
3). They vaccinated primates with
whole-cell P. gingivalis, and demonstrated partial protection against
experimental periodontitis. Interestingly, they found that the levels
of specific antibodies against P. gingivalis were high in all animals that
were exposed to the bacteria, immunized and non-immunized, and
antibody production was not able
to explain the protection achieved.
They also tested levels of specific
molecules that are secreted by inflammatory cells in the gingival
crevicular fluid and found that vaccination was successful in modifying the host response to the infection, thereby reducing the levels of
the inflammatory mediator
Prostaglandin E2 (PG-E2). There
was a correlation between PG-E2
and bone loss: the lower the level of
the mediator, the less bone loss observed.
This was the first proof of principle. From then on, significant efforts were made in identifying molecules that are virulence factors
and may serve as good candidates
for vaccine development, with
most researchers concentrating on
molecules derived from P. gingivalis. Some of its proteins were isolated and used for immunization
studies. Many investigators focused on a specific group of important enzymes—cysteine proteases,
which are considered to be essential for P. gingivalis survival and for
disease pathogenesis.
Thirteen years after their pio-
neering experiment, Page’s team
also tested the safety and efficacy of
a vaccine containing a cysteine protease of P. gingivalis (Oral Microbiology and Immunology, 2007, Vol.
22, Issue 3). Following their first experiment, they vaccinated primates with the cysteine protease
and induced experimental periodontitis by inoculation of P. gingivalis.This vaccine was also found to
induce partial protection against
experimental disease, suggesting
the possibility of developing a vaccine using a single molecule of P.
gingivalis.
Modern molecular biology offers new approaches to making vaccines by cloning genes from bacteria, expressing the protein antigen
in other bacteria in culture and isolating the pure protein in the laboratory. This makes the preparation
safer and easier to prepare. Professor Mike Curtis from the Queen
Mary, University of London has
cloned a gene containing the code
for the adhesive part of an important cysteine protease of P. gingivalis, rgpA. The vector in bacteria
was expressed by our own Dr. Asaf
Wilensky, who produced a recombinant peptide and used it in vaccination experiments with mice, in
which periodontitis was induced
by inoculation of P. gingivalis, and
bone loss was assessed using microCT (Journal of Periodontology,
2005, Vol. 76, Issue 8).
By Wim Crielaard, Academisch Centrum Tandheelkunde Amsterdam, the
Netherlands
Being able to analyse the oral microbiome is of particular relevance
and importance because it is well
known that micro-organisms cooperate collectively in a polymicrobial ecosystem, causing chronic
oral infections, such as periodontitis, gingivitis, peri-implantitis,
stomatitis, caries and endodontic
infections.
Studies of cultivable sub-gingival micro-organisms had already
shown that the predominant bacteria in periodontally healthy sites
are Gram-positive facultative rods
and cocci. In periodontitis, there is
a decrease in the number of these
“healthy” organisms and an increase in the number of “pathogenic” Gram-negative rods and
spirochetes. An ecological disturbance induces this pathogenic
shift: if the healthy symbiotic balance between the host and the micro-organisms present in the sub-
gingival ecosystem is disturbed, for
example, by an unhealthy diet,
poor oral hygiene or smoking, periodontal disease is likely to occur.
Indeed, culturing sub-gingival
micro-organisms has provided considerable knowledge on the pathogenic bacteria associated with periodontitis, but unfortunately this approach is limited by the fact that it
focuses (by definition) on cultivable
micro-organisms. As has been underlined frequently in the past,
many oral bacteria cannot be cultivated and therefore conclusions
are drawn on an incomplete picture. With this in mind, and because
scientists started to realise that the
polymicrobial ecosystem actively
sustains oral health, even before
NGS, molecular microbial analyses
had been developed, which give a
better, more complete overview of
the oral microbial ecology in health
Yet, there is hope. Better understanding disease pathogenesis in
animal models will help us in developing the right vaccine for the right
target.
Prof. Shapira will be presenting
today during the EFP/AAP session, “Latest therapies and
emerging technologies”,
14:00–15:30, Room Strauss 2–3.
A recent hypothesis is that targeting P. gingivalis may have a community-wide impact on the flora,
and may be important for prevent-
New insights into the complexity
of microbiological infections
Modern molecular analyses and
in particular next-generation sequencing (NGS) techniques have
revolutionised oral microbiology.
Owing to the fact that we can, relatively cheaply, analyse millions of
(bacterial) DNA sequences within a
few days, we now have the capability, for the first time in history, to
recognise all oral bacteria, the oral
microbiome, present (at different
locations) in the oral cavity. The
term “human microbiome” is defined as the ecological community
of commensal, symbiotic and pathogenic micro-organisms that share
our body space. Indeed, since the
first use of NGS for oral microbial
communities in 2008, there has
been an avalanche of NGS studies
directed towards oral infections.
ing chronic periodontitis. In an elegant preliminary yet unpublished
experiment, Wilensky demonstrated that vaccination with the recombinant peptide was able to provide 50 per cent protection, similar
to a vaccine with whole bacteria,
and induce changes in the host response to the infection. This experiment proved the principle that a
recombinant protein can be used as
a vaccine for periodontitis.
So, how close are we to developing a periodontitis vaccine in 2012?
Well, we still lack data from clinical
trials in animals and there is not
enough preclinical data. Therefore,
we are still far from phase III experiments in humans.
and during disease. Many molecular microbial analyses have been
targeted at a selection of (pathogenic) micro-organisms, but only
open-ended approaches, where
there is no selection for specific
species to be detected, can be used
for oral microbiome studies.
The open-ended approach that
has been most widely used for oral
microbial communities and oral infections is the 16S rRNA gene clonelibrary approach. In this approach,
bacterial 16S rRNA genes, from
which the bacterial lineage can be
deduced, are extracted from clinical, for example sub-gingival, samples. Using molecular biological
techniques, these genes (lineage
codes) are copied and stored in biological libraries (i.e. living bacterial
cells). Subsequently, the DNA codes
of the 16S genes are revealed using
traditional (Sanger) sequencing
methods and the bacteria present
in the original sample can be classified. Indeed, by using this technique, several uncultivated bacteria were found to be associated with
periodontitis, but after the first
NGS study in which several orders
of magnitude (i.e. millions) bacterial 16S DNA codes were analysed, it
became clear that so far we had
only explored the tip of the iceberg.
In the past two years, several laboratories have used NGS techniques to identify the pathogenic
microbiomes that cause periodontitis, peri-implantitis and other oral
infections and have compared
these with the oral microbiomes of
healthy subjects to understand the
ecological shifts that accompany
the transition from a healthy state
towards disease.
During the presentation at Europerio 7, the advantages and challenges of using NGS techniques (in
comparison with more traditional
techniques) in studying oral microbial infections, as well as recently
obtained new insights into the complexity of these polymicrobial infections, will be presented.
Prof. Crielaard will be presenting today during the periodontology session, “New insights into the host response in periodontitis”, 10:30–12:00, Room Strauss 2–3.
[8] =>
Standard_300dpi
business
8
EUROPERIO Vienna 2012–7 June
EUROPERIO Vienna 2012—Exhibitors List
Company
Booth
A
Company
Booth
Curaden International AG
ACTEON
ADIN Dental Implant
Systems Ltd.
Advanced Dental
Diagnostics BV
Aesculap AG
American Academy
of Periodontology
American Dental Systems
American Eagle
Instruments Inc.
Anthogyr
Astra Tech AB
37
49
16a
12c
18b
6c
28b
7a
10a
B
BDIZ EDI
19f
Bicon Europe Ltd.
9c/9d
BIEN-AIR Dental SA
48b
BioGaia AB
13a
BioHorizons, Inc.
55
Biolase
61a
Biomatlante
25a
Biomet 3i
39 & F4
botiss biomaterials
44b
Bredent Medical
GmbH & Co. KG
52b
brumaba GmbH & Co. KG
45b
BTI Biotechnology Institute
5d
C
CAMLOG Biotechnologies AG 29
Carl Zeiss Meditec
43b
Chimo Dental
47b
CMS Dental
54a
Consult-PRO/
DHC Marketing Inc.
19c
CORTEX Dental Implants
Industries Ltd.
5c
Cumdente GmbH
12b
About the
Publisher
Editorial/
Dental Tribune International
Administrative Office GmbH
Holbeinstraße 29
04229 Leipzig, Germany
Phone
+49 341 48474-302
Fax
+49 341 48474-173
Internet
www.dental-tribune.com
Publisher
Torsten Oemus
Director of Finance
and Controlling
Dan Wunderlich
Managing Editor
Daniel Zimmermann
Editorial Assistant
Claudia Duschek
Product Manager
Bernhard Moldenhauer
Production Executive Gernot Meyer
Production
Matthias Abicht
today Europerio will appear at Europerio 7, Vienna, 6–9 June,
2012.
The magazine and all articles and illustrations therein are protected by copyright. Any utilisation without prior consent
from the editor or publisher is inadmissible and liable to prosecution. No responsibility shall be assumed for information
published about associations, companies and commercial
markets. General terms and conditions apply, legal venue is
Leipzig, Germany.
Company
Booth
Company
Booth
43c
DTI/Photo Ing. Schieder Markus
D
DCI-Dental Consulting GmbH 48c
Degradable Solutions AG
15b
Dentack Implants Ltd.
3b
DENTAID
33
Dental R.A.T.
2a
Dental A2Z Ltd.
45a
DENTAL RATIO
11a
Dentatus AB
28b
Dentium Co., Ltd.
5a
DENTSPLY Friadent
41
Deppeler SA
15c
Dexcel Pharma GmbH
47a
Dürr Dental AG
30b
E
EMS
Electro Medical Systems
European Association
of Osseointegration
58 & F3
18a
F
Florida Probe
Fotona D.D.
43a
11c
LM-Instruments Oy
LOSER & CO GmbH
G
GABA/Colgate
Geistlich Biomaterials
GlaxoSmithKline Consumer
Healthcare
GluStitch Inc
Greiner Bio-One GmbH
40
36
17b
11d
8b
H
Hager & Meisinger GmbH
Hager & Werken
GmbH & Co. KG
Hain Lifescience GmbH
HANS Korea
Hartzell & Son, G.
Heraeus
HU-FRIEDY Mfg. Co. LLC
L
28a
25b
14b
54b
8d
42
23
Q
21b
28b
J
J. Morita Mfg. Corp.
JETTS Technology Co., Ltd.
Johnson & Johnson
18c
2b
35
M
RIEMSER Arzneimittel AG
Maxillent Ltd.
51
Mectron SPA
30a
Meda Pharma GmbH
26b
MegaGen Implant Co., Ltd.
6b
Meta
28c
MIS Implants
Technologies
57 & F2
N
Neobiotech
Neoss GmbH
Nissin Dental Products Inc.
Nobel Biocare
NovaBone Products
Nucleoss Implant
19a
9c
50a
59
17c
26a
O
Omnia Spa
9a
Oral-B / Procter & Gamble 60 & F1
Oral-Prevent
26c
orangedental GmbH & Co. KG 14c
Osseous Technologies
of America
1
Osstell
54c
OSSTEM Germany GmbH
61b
OsteoBiol by Tecnoss
15a
Osteogenics Biomedical, Inc. 13d
Osteology Foundation
17a
K
KaVo
Kea Software
Keystone Dental
16b
11b
31
44a
R
I
IDEA – Interdisciplinary
Dental Education Academy 62a
Implant Direct Sybron
Europe AG
27b
ITI Foundation for the
Promotion of Oral Implantology 8c
Quintessenz Publishing
14a
S
SICAT GmbH & Co. KG
8a
Sirona Dental Systems GmbH 5b
SOREDEX
47c
Southern Implants
10b
Stoma Dentalsysteme
GmbH & Co KG
10c
Straumann
(Institut Straumann AG)
38
successpharm GmbH
62d
SUNSTAR
32
Swissmeda AG
48d
T
Tecdent HandelsgmbH
4
TePe Mundhygieneprodukte
Vertriebs-GmbH
52a
Thommen Medical
53
Tigran Technologies
9b
TRI Dental Implants Int. AG 30c
U
Ustomed Instrumente
13b
W
W&H Dentalwerk Bürmoos
GmbH
Wiley-Blackwell Publishing
27a
7b
P
Philips
Planmeca Oy
34
6a
Z
Zimmer Dental
The list is based on information provided solely by the exhibitors. Dental Tribune does not take responsibility for correctness or completeness of the information.
56
[9] =>
Standard_300dpi
Temporary Gingival
retraction system
Get into
a new prophylactic world
Prevent and treat peri-implantitis
Come and visit us on
booth No. 37
Join Acteon Masters Classes on www.acteongroup-events.com
$&7(21DY*XVWDYH(LIIHO%30(5,*1$&FHGH[)5$1&(
7HO )D[ (PDLO LQIR#DFWHRQJURXSFRPZZZDFWHRQJURXSFRP
– RCS Paris B 337 934 483 – 026656
Acteon proudly supports
[10] =>
Standard_300dpi
industry
10
PLENTY ON DISPLAY BY PHILIPS
Gold Sponsor Philips is inviting participants of the Europerio
congress to its booth, where the
company will not only present its
Sonicare sonic and brush head
technology, but also studies as
its AirFloss one year ago at IDS
Cologne.
In a survey to be conducted at
Europerio, Philips is also hoping to
evaluate latest trends and opinions
in regard interdental hygiene. Par-
About a year ago, Philips Sonicare introduced the Sonicare AirFloss to healthcare professionals at IDS. Now, a television ad campaign presents this new easy-to-use technology for
interdental cleaning to consumers. Starting with Germany and the Netherlands, the ads
provide information about the technology, the use and the products to a broader audience.
well as information about strategies for dental plaque biofilm
management. Moreover, Philips
will celebrate the introduction of
ticipants will have the chance to
win ten Sonicare AirFloss, the company said.
According to Philips, there will
EUROPERIO Vienna 2012–7 June
be plenty opportunity for dialogue
at Europerio. Studies will be discussed and new design can be studied. Participants will be able to test
the Sonicare Diamond Clean,
Philips Sonicare’s new flagship
from its toothbrush product line.
For the first time, the company will
also present the new Sonicare Sensitive Mini brush head to a
broader professional audience.
Philips said that visitors can
profit from its special Euro
Perio offers. With every order,
the company will provide a free
sample of the Sonicare Sensitive Mini brush head.
new functionality and a revolutionary brush
head design.
Video Philips Sonicare
In addition, participants
Owing to cliniTV campaign
To watch the video, simply scan
will also find information about
cal validation
the QR code with your Smartphone (e.g. Reader Quick Scan).
the new Philips ZOOM teeth
of its products,
whitening products at the comSonicare is the
pany’s booth.
most recommended brand of sonic toothPhilips Sonicare is a company brushes worldwide, the company
that has defined new standards in said.
dental hygiene. Based on the success of the patented sonic technolPhilips Sonicare also says to be
ogy, the latest generation of Soni- successfully committed to develcare dental brushes also provides oping new products for dental
POTENTIAL OF ENAMEL MATRIX DERIVATIVE STILL NOT FULLY EXPLOITED
Commercially available enamel
matrix derivative (EMDs), such
as Straumann Emdogain, has become well established on the
market. It is used in dentistry
when regeneration of soft and
hard tissues surrounding teeth
is needed to restore a functional
periodontal ligament—a requirement for treating intrabony defects, furcation defects
and recession defects.
tion still have to be fully explored and exploited. During
the Straumann’s corporate forum at Europerio 7, clinical and
histological evidence documenting the effectiveness of
coronally advanced flaps combined with the use of Emdogain
for the treatment of recession
defects will be discussed today.
Properties of commercially
available EMD will also be revealed.
STRAUMANN,
SWITZERLAND
www.straumann.com
Booth 38
STRAUMANN CORPORATE
FORUM “PROVEN CONCEPTS AND
INNOVATIONS IN PERIODONTAL
AND IMPLANT DENTISTRY”
Winning case of Dr Da Silva and co-workers featured at Growth in recession—
An Esthetic case selection on Straumann
Emdogain
Furthermore, combining
commercially available EMD
with various bone grafting materials has shown to improve the
regenerative periodontal outcome. In addition to the regenerative benefits, patients that
were subject to guided tissue regeneration (GTR) reported less
pain and swelling when commercially available EMD was
used in the process.
Despite the extensive use of
commercially available EMD in
clinical practice, its benefits for
soft and hard tissue regenera-
– Thursday, 7th June 2012, 12:15 to
13:45
– Venue: Room “Strauss 2–3”
(ground floor), Congress center,
Messe Wien, Vienna
– The Forum will be held in English
– Lunch boxes will be provided.
Having pioneered many influential
technologies and techniques in its
field, Straumann embodies the tradition to advance dental regeneration,
restoration and replacement, as well
as patient care. Straumann invests
considerable resources in the development of innovative products and
solutions for the benefit of patients
and customers. In this corporate forum, renowned speakers present
and discuss the latest innovations in
guided bone regeneration and implant concepts, and the long-term
evidence and predictability of regeneration in periodontology.
HERE
Chairman
David L. Cochran, DDS, PhD is a graduate of the University of Virginia and
received his DDS, and PhD, in Biochemistry from the Medical College
of Virginia (MCV). He also was trained
in Periodontology from the Harvard
School of Dental Medicine. Dr.
Cochran is currently Professor and
Chairman of the Department of Periodontics at The University of Texas
Health Science Center at San Antonio, Dental School.
Speakers
TREATMENT OF RECESSION DEFECTS: LONG-TERM EVIDENCE AND
PREDICTABILITY OF EMDOGAIN®
Dr. Michael McGuire, DDS and Certificate of Periodontics, Emory University School of Dentistry, Atlanta,
GA/ USA. He is a director of the
American Board of Periodontology
and has served as president of numerous dental organizations, including the American Academy of
Periodontology and the American
Academy of Periodontology Foundation.
CURRENT ADVANCES IN GUIDED
BONE REGENERATION MATERIALS
AND IMPLANT SURFACES
Prof. Dr. Nikolaos Donos, DDS, MS,
FHEA, FRCSEng, PhD. Head & Chair of
Periodontology and the Director of
Clinical Research at the UCL-Eastman Dental Institute and Director of
the Oral Health Theme at the
UCLH/UCL Comprehensive Biomedical Centre in London/UK.
ESTABLISHED AND NEW IMPLANT
CONCEPTS
Stephen T. Chen, BDS, MDSc, PhD,
Senior Fellow, Centre for Oral Health
Science, School of Dental Science,
The University of Melbourne in Melbourne/Australia.
plaque biofilm management. Cooperation and dialogue with scientists and industry experts lead to
innovations and trend-setting concepts. Sonicare products were
thoroughly tested in clinical studies, proving their high degree of effectiveness and their clinical performance which includes the Sonicare AirFloss and its Microburst
Technology.
PHILIPS SONICARE,
THE NETHERLANDS
www.sonicare.com
Booth G34
PRACTICAL HANDS-ON COURSES HOSTED BY
ACTEON
Current issues in periodontics
and implant treatment as well as
in-depth discussions involving
top-class speakers from around
the world will be in focus of the
world’s largest and most important conference for periodontology. Supporting Europerio 7 as a
Platinum Sponsor, the French
Acteon Group has announced to
The Air-N-Go with direct connection to the chair was designed
for ultra-active supra-gingival polishing as well as sub-gingival periodontal diseases and peri-implantitis treatment. According to the
manufacturer, it can be instantly
converted into a perio system
with the help of an optional AIR-NGO PERIO Kit comprising an ultra-
participate in the congress’ trade
exhibition as well as to sponsor
three presentations in the official
programme. In addition, the company will host three hands-on
courses and two workshops with
internationally renowned experts in periodontics and implant
surgery.
fine PERIO nozzle, green PERIO
powder tank and glycine-based
PERIO powder.
Today, two hands-on workshops will be open to participants
of Europerio. Starting at 9:00, Dr
Volker Clar and Prof. Ulrich P.
Säxer will focus on the company’s
dual purpose air polisher Air-NGo in an English session titled “Advanced methods of conservative
treatment of periodontitis and
peri-implantitis”. In the afternoon,
a similar presentation will be presented by Wolf D. Grimm to a German-speaking audience.
Both workshops will be held in
the Hospitality Suite 6A at the
Gallery in Hall B.
Despite a number of scientific
lectures, the Acteon Group will
also hold two presentations on
prophylaxis, a hands-on course on
piezo-ultrasonic surgery and a
workshop focusing on 3-D diagnostics throughout the next three
days.
As a specialist in fields like periodontal therapy, diagnostics,
surgery, implantology and dental
hygiene, the Acteon Group and its
three business divisions for imaging, equipment and pharmaceuticals, is committed to scientifically
proven performance and patientoriented dentistry.
ACTEON GROUP, FRANCE
www.acteongroup-events.com
Booth 37
[11] =>
Standard_300dpi
Scaling has never been
so relaxing and easy
W
E
N
Scan the QR code
with your mobile
telephone for more
information on Tigon+
The new W&H Tigon+ is a piezo scaler without equal: the warm irrigant
spray protects even the most sensitive teeth, making treatment more
comfortable. The three different power modes and five present programmes
allow you to work even more safely and efficiently.
wh.com
Ultimate Piezo Scaler Technology
[12] =>
Standard_300dpi
industry
12
TIGON/TIGON+
With Tigon+, the Austrian dental manufacturer W&H said to have
developed a piezo scaler that optimally meets the needs of both the
patient and the dentist. Patients in
particular benefit from a temperature-controlled fluid that helps to
avoid irritations even on sensitive
teeth and gums. The heating can be
switched off, if required, and is
easy to control via a display. According to the company, three tem-
EUROPERIO Vienna 2012–7 June
perature setting are available
with Tigon+.
tooth on the display shows which
programme is currently in use.
W&H’s latest piezo scaler
also comes with five preset programmes for efficient use in
prophylaxis, periodontology,
endodontics, and restorative
procedures. In addition, settings for the fifth programme
can be selected freely by the dentists or dental hygienist. A navi-
Three power modes allow the
user to define the scaler power
according to their preferences,
which is supposed to give dentists
and dental technicians the right
amount of pressure without having to think about whether they
treat the tooth too gently or too
hard.
LED technology offering contrast sensitivity similar to daylight
allows for improved lighting conditions and visual perception. The
handpiece and LED ring can be
thermally disinfected and sterilised, the company said.
W&H, AUSTRIA
www.wh.com
Booth 27a
AD
DENTAL HYGIENE RESEARCH
MEETING
Non Surgical Periodontal Treatment:
How to Conciliate Scientific Evidences and Clinical Practice
NOBELREPLACE
EVOLVES
Suitable for both experienced restorative clinicians and
surgical implant users, Nobel
Replace has evolved into two
new versions, both of which retain the key features of Nobel
Replace Tapered including the
tapered implant design, as well
as the standardised step-by-step
drilling protocol.
Pisa, December 14th -15th 2012
Preliminary program
PROF. BIRGITTA SODER
Non Surgical Periodontal Treatment:
Associations between Oral Biofilm/Dental Plaque and Life threatening Diseases.
DR. DAGMAR ELSE SLOT
Do lasers/photodynamic therapy have a role in Non Surgical periodontal treatment?
DR. MARIJOLIN HOVIUS
Why and how should you promote smoking cessation in your dental hygiene practice.
PROF. CAREN M. BARNES
Traditional Polishing and Airpolishing: Conversion of Research to Clinical Practice.
PROF. MARIANO SANZ
The use of antimicrobials in the secondary prevention of periodontal infections.
DR. MARYANN CUGINI
The use of systemic antibiotics to treat periodontal infections.
DR. JEANIE SUVAN
Patient-Centred Non Surgical Periodontal Therapy: Evidence vs Practice.
DR. FRANCES DOHERTY GENCO
(Definition phase)
Istituto Stomatologico Toscano
Via Aurelia, 335 - I-55043 Lido di Camaiore (Italy)
Phone +39 0584 6059888/9 - Fax +39 0584 6058716
E-mail: centro.odontoiatria@usl12.toscana.it
Location
Hotel Abitalia Tower Plaza - Via Caduti del lavoro, 46 - I-56122 Pisa (Italy)
Phone +39 050 7846444 - Fax +39 050 7846445
Organizational Secretary Office
Tueor srl - Corso Sebastopoli, 225 - I-10137 Torino (Italy)
Phone +39 011 0463350 - segreteria@tueor.com - www.tueor.it
Istituto
Stomatologico
Toscano
NobelReplace Platform Shift and Conical Connection. (DTI/Photos courtesy of
Nobel Biocare)
According to Nobel Biocare,
NobelReplace Conical Connection (CC) has been designed to increase soft tissue volume. This
new iteration adds an advanced
third generation internal conical
connection and built-in platform
shifting to the NobelReplace implant body.
NobelReplace Platform Shift
(PS), on the other hand, retains
the internal tri-channel connection to which experienced NobelReplace Tapered users are accustomed, while adding the platform-shifting feature now available in NobelReplace CC.
Platform shifting promotes expanded tissue volume at the soft
tissue interface, thereby creating more natural-looking aesthetics, while the proven trichannel connection of the NobelReplace PS design provides familiar tactile feedback. Like all
other NobelReplace tapered implants, the new versions mimic
the shape of a natural tooth root.
Designed for high initial stability, they can be placed in both extraction sockets and healed sites.
With the latest innovations
Nobel Biocare’s versatile implant portfolio has been further
expanded to accommodate individual treatment needs of dental
professionals. The complete assortment includes bone- and tissue-level implants for all indications, bone types and surgical
protocols.
NOBEL BIOCARE,
SWITZERLAND
www.nobelbiocare.com/replaceccps
Booth 59
[13] =>
Standard_300dpi
industry
EUROPERIO Vienna 2012–7 June
13
Change your patients’ lives with denture comfort
In the event patients become
edentulous, dentures offer many
advantages compared to other alternatives. They are aesthetically
pleasing, easy to maintain and
cost effective. However, these
benefits are often hampered by
patient discomfort and may lead
to difficulty in chewing, pronunciation and freely expressing facial
expressions such as smiling or
laughing. To compensate, denture
wearers often change their daily
routine and diet in ways that expose them to greater health risks.
Clearly this situation often
leaves dentists less excited about
proposing dentures as a viable solution for their edentulous patients. Paul Homoly, DDS, president of Homoly Communications,
suggests the shortcomings of a traditional denture treatment prevent most dentists from being content with this treatment option for
their patients. Dentatus also
found that some may be prolonging tooth extractions, particularly
in the mandibular arch, because
of poor retention of dentures and
continual bone resorption.
There is, however, a treatment
option that can dramatically improve the patient experience with
a lower denture and prevent bone
resorption. Meijer et al., reports
that patients with mandibular
overdentures supported by implants are more satisfied compared to patients without the implants. With the advent of narrowdiameter implants, this treatment
option is now more accessible
than ever before. Dentatus has
found that narrow-body implant
retained overdentures can overcome many hurdles providing
more patients with access to the
latest and most beneficial treatments available.
University Department of Implant Dentistry published a
study in Practical Procedures &
Aesthetic Dentistry stating, “In
this study, full mandibular dentures supported by non-splinted,
dome-shaped NBIs provided immediate occlusal loading and
function with high survival rates
of both the NDIs (i.e., 94.1 per
cent) and prostheses (i.e., 100 per
cent).”
These results support wellknown literature about implant
design and materials in the following ways; Atlas narrow-body dental implants are composed of
Ease of restoration
Site preparation in the atrophic
anterior mandible often confronts
practitioners with challenging
anatomic limitations such as exaggerated facial lingual bone angulation created by the submental fossa
and the mentalis muscle insertion.
As such, angulation of the implants
may vary from site to site resulting
in non-parallel implant placement.
During the retrofit process, this can
lead to attachments protruding out
of the denture flange or may
weaken the denture by drilling into
the denture teeth.
With Atlas implants a silicone
material of flowable nature (TufLink, Dentatus) offers cushioned
support designed to maximally
engage the dome-shaped head to
achieve clinically significant retention even in these less than
ideal conditions.
moved for the osteotomy. The tapered one-piece implant design
eliminates the microgap, which is
related to crestal bone loss, facilitates one stage surgery and provides immediate restoration. It is
also more conducive to a flapless
implant placement. Utilising a
minimally invasive flapless procedure with an immediate
restoration eliminates many post-
operative challenges as well as reduces total treatment time.
Isn’t it time you looked into this
treatment option to restore quality of life for your denture patients? Dentatus makes it easy for
you to get started with its half-day
hands-on workshops. All the materials for your first case are included in the registration fee.
AD
3 Tage
Mittelpunkt
für Dentalprofis!
The reline provides for an individualised custom fit every time,
the first time. In addition, the silicone based reline provides retention without rigidity, thereby reducing unwanted lateral forces
further increasing integration potential, ultimately protecting the
implant.
Advantages
(DTI/Photos courtesy of Dr Wolfram Bücking, Germany)
Research
Atlas narrow-diameter implants are built and clinically
proven for long-term use. They
are tested with university-based
research from the around the
world; the first results were published in 2004. In 2007, Dr SangChoon Cho, Dr Stuart Froum and
his colleagues from the New York
grade V, titanium alloy, and the
threaded portion of the implant is
mechanically roughened to increase surface area and maximise
the bone-implant interface. The
tapered design better facilitates
implant placement, promotes initial stability and better distributes
occlusal loads along the implant
body.
Atlas narrow-body implants offer several advantages. First and
foremost, they expand the patient
population that is eligible for this
treatment. Narrow-body implants
make it easier to maintain adequate buccal-lingual bone dimensions and proper implant spacing
without the need for ridge augmentation. The narrow-body diameter allows a thicker buccal
bone because less bone is re-
w
ts
Ticke
Jetz t llen:
beste 012 .ch
ental2
w w.d
Freitag, 15. Juni 2012: Eat’n’Greet und
Dental Club Night im Kornhauskeller.
Tickets gleich mitbestellen – es hät nur so lang’s het!
[14] =>
Standard_300dpi
14
What’s on
Sand in the City (Bar)
Address: Lothringerstraße 22,
14:00 to 24:00
www.sandinthecity.at
Since 2007, Vienna’s restaurant owners have been coming
together to create that holiday
feeling for citizens and visitors
alike. Every year, a unique beach
travel
EUROPERIO Vienna 2012–7 June
location is set up in the middle of
the city. Jacuzzis, a swimming
pool, cocktail bars and even a
massage lounge render Sand in
the City probably Vienna’s
coolest summer location. Thirteen different bars offer hot and
cold drinks, cocktails, various international foods, as well as beer
specialties. In addition, sports
fans can play beach volleyball on
two courts constructed from 250
tons of the finest quartz sand.
Gold (Exhibition)
Venue: Lower Belvedere,
10:00 to 18:00
www.belvedere.at
During the Middle Ages, gold
was frequently used in art production but it disappeared in the
subsequent centuries until the
material was rediscovered towards the end of the 20th century. This special exhibition on
gold and its use in contemporary
arts showcases 200 works by
125 artists, highlighting the different applications of the precious metal and juxtaposing
traditional visual elements with
contemporary art. On view
are familiar examples and
numerous new discoveries, including works by Stephan
Balkenhol, Willi Baumeister,
William Blake, Gerhard Richter,
Victor Vasarely, Andy Warhol
and Franz West.
AD
S N
R
O
A
I
E IT
Y
D
0
A
2 R
T
F
O
Charity concert (Music)
Venue: University of Vienna,
ballroom, 19:30
www.oejab.at
This benefit concert will be
held for children living in the
streets of Ouagadougou, the capital of the West African country
Burkina Faso. Together with the
American Youth Symphonic Orchestra, the university choir will
perform works by Josef Weinberger, Ottorino Respighi and Antonín Dvořák. The event is hosted
by Art & Culture without Borders,
a collaborative project of the Austrian Young Workers Movement
and an Austrian non-profit student organisation, to raise money
for their education project for
African children in need.
Summer Night concert
(Music)
Venue: Schönbrunn Palace
gardens, 21:00
www.sommernachtskonzert.at
20th INTERNATIONAL DENTAL FAIR
11. - 13. 10. 2012
Prague Exhibition Grounds Holesovice
(DTI/Photo Richard Schuster, Austria)
www.pragodent.eu
In front of the Neptune fountain in the picturesque gardens
of the Schönbrunn Palace, the
Vienna Philharmonic Orchestra
will give an open-air concert
tonight under the musical direction of Gustavo Dudamel, a
young talent from Venezuela.
Works by Tchaikovsky, Mussorgsky and Strauss will be performed, among others. The concert is an annual attraction for
thousands of concert-goers. Admission is generally free and the
baroque gardens of Schönbrunn, which is a UNESCO
World Heritage Site, offer visitors to the city an exceptional
setting for a special musical experience.
Glacis Beisl (Restaurant)
Address: Museumsplatz 1
www.glacisbeisl.at
Professional partners
Media partners
This typical Viennese bistro is
located at the end of the Museums
Quartier and therefore the ideal
place to rest after a visit to one of
numerous museums. The term
“Beisl” is derived from the Yiddish word for “house” and the
restaurant is characterised by its
plain fare and cosy atmosphere.
Hot food is served from 12:00 to
23:00. The menu offers traditional Viennese dishes like famous Viennese schnitzel,
goulash and a number of desserts
such as Kaiserschmarrn and
Palatschinken, Austrian versions of the pancake. The bistro
also offers a selection of light and
vegetarian meals. Visitors are invited to enjoy the house’s selection of fine wines and beers in the
seating area in the adjacent
shady garden.
[15] =>
Standard_300dpi
© MIS Corporation. All rights Reserved.
MAKE IT
SI M PLE
LINE OF SUCCESS... MAKE IT SIMPLE
*NLÇ?QC
J?LÉIH;FAI;FÉ ?=;NÉ?P?NH>?LÉM;H>MB;MCM_ÉHIMDNÉM;FC@? $@RINAIM;H??>P?_>FIO?MI
JNMINLGCH>;ÉP?FF;ÉF?H>INL?;LÉMI@NFÆFFCM *NLÉCGJFC=CMRCÉRINL
ÉN==?ÉÉ .IF?;LH;
[16] =>
Standard_300dpi
Smaller and stronger.
Safe implant placement in
areas with limited space.
Maximum material strength
and strong sealed connection.
High initial stability and
bone preservation.
CELEBRATE THE INNOVATION OF
OSSEOINTEGRATION WITH US!
June 7: Patient-oriented treatment
approaches remain the key to success
June 8: Maintenance of marginal
bone around implants
Both sessions start at 12.15 in room
Strauss 1. Lunch boxes will be provided.
It’s called NobelActive 3.0. This unique implant is the
ideal solution for narrow spaces in the anterior region.
The drilling procedure is designed to retain as much bone
as possible, while the implant body and thread design
condenses bone during insertion enhancing initial stability. The sharp apex and cutting blades enable you to
adjust the implant position for optimal restorative orien-
tation. Together with the strong sealed connection and
built-in platform shifting, NobelActive 3.0 allows you to
safely produce excellent esthetic results. After 45 years
as a dental innovator we have the experience to bring
you future-proof and reliable technologies for effective
patient treatment. Their smile, your skill, our solutions.
Visit nobelbiocare.com/active3
© Nobel Biocare Services AG, 2012. All rights reserved. Nobel Biocare, the Nobel Biocare logotype and all other trademarks are, if nothing else is stated or is evident from the context in a certain case, trademarks of Nobel Biocare.
Disclaimer: Some products may not be regulatory cleared/released for sale in all markets. Please contact the local Nobel Biocare sales office for current product assortment and availability.
)
[page_count] => 16
[pdf_ping_data] => Array
(
[page_count] => 16
[format] => PDF
[width] => 794
[height] => 1134
[colorspace] => COLORSPACE_UNDEFINED
)
[linked_companies] => Array
(
[ids] => Array
(
)
)
[cover_url] =>
[cover_three] =>
[cover] => ![today EuroPerio7 Vienna 7 June 2012]()
[toc] => Array
(
[0] => Array
(
[title] => Seventh congress of the European Federation of Periodontology to present the latest research and cutting-edge technology
[page] => 01
)
[1] => Array
(
[title] => Colgate-Palmolive launches Oral Health Network
[page] => 01
)
[2] => Array
(
[title] => Welcome
[page] => 02
)
[3] => Array
(
[title] => “Our growth is definitely driven by innovation and quality” - An interview with Gilles Pierson - CEO of the Acteon Group
[page] => 04
)
[4] => Array
(
[title] => “Good long-term treatment results depend on periodontal maintenance therapy” - An interview with Dr Oystein Fardal - Norway
[page] => 06
)
[5] => Array
(
[title] => Science & Practice
[page] => 07
)
[6] => Array
(
[title] => Exhibitors List
[page] => 08
)
[7] => Array
(
[title] => Industry
[page] => 10
)
[8] => Array
(
[title] => What’s on
[page] => 14
)
)
[toc_html] =>
[toc_titles] => Seventh congress of the European Federation of Periodontology to present the latest research and cutting-edge technology
/ Colgate-Palmolive launches Oral Health Network
/ Welcome
/ “Our growth is definitely driven by innovation and quality” - An interview with Gilles Pierson - CEO of the Acteon Group
/ “Good long-term treatment results depend on periodontal maintenance therapy” - An interview with Dr Oystein Fardal - Norway
/ Science & Practice
/ Exhibitors List
/ Industry
/ What’s on
[cached] => true
)
